welcome
Reuters

Reuters

Health

Health

J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

Reuters
Summary
Nutrition label

79% Informative

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara .

The company, along with partner Sandoz , said earlier on Monday that its biosimilar Pyzchiva is now available in the United States .

Teva Pharmaceuticals and Alvotech last Friday launched Selarsdi , a biosimilar to the autoimmune drug.

At least six close copies are expected to launch in the U.S. this year .

VR Score

85

Informative language

88

Neutral language

80

Article tone

formal

Language

English

Language complexity

73

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links